Even IL-6 blockade in cancer patients treated with immune checkpoint blockade is viewed as a win-win strategy because combined IL-6 blockade and immune checkpoint blockade abrogates immunotherapy toxicity and promotes tumor immunity (58). This evidence concerns the gene IL6 and cancer.